AU2014357450B2 - Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof - Google Patents

Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof Download PDF

Info

Publication number
AU2014357450B2
AU2014357450B2 AU2014357450A AU2014357450A AU2014357450B2 AU 2014357450 B2 AU2014357450 B2 AU 2014357450B2 AU 2014357450 A AU2014357450 A AU 2014357450A AU 2014357450 A AU2014357450 A AU 2014357450A AU 2014357450 B2 AU2014357450 B2 AU 2014357450B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
ser
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014357450A
Other languages
English (en)
Other versions
AU2014357450A1 (en
Inventor
David Kostyal
Virginia RAYMOND
Jonathan A. Welt
Rachel S. Welt
Sydney Welt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WELT BIO-MOLECULAR PHARMACEUTICAL LLC
Original Assignee
WELT BIO MOLECULAR PHARMACEUTICAL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WELT BIO MOLECULAR PHARMACEUTICAL LLC filed Critical WELT BIO MOLECULAR PHARMACEUTICAL LLC
Publication of AU2014357450A1 publication Critical patent/AU2014357450A1/en
Priority to AU2019229346A priority Critical patent/AU2019229346A1/en
Application granted granted Critical
Publication of AU2014357450B2 publication Critical patent/AU2014357450B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014357450A 2013-12-03 2014-12-01 Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof Active AU2014357450B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019229346A AU2019229346A1 (en) 2013-12-03 2019-09-11 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911186P 2013-12-03 2013-12-03
US61/911,186 2013-12-03
PCT/US2014/067957 WO2015084736A2 (en) 2013-12-03 2014-12-01 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019229346A Division AU2019229346A1 (en) 2013-12-03 2019-09-11 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Publications (2)

Publication Number Publication Date
AU2014357450A1 AU2014357450A1 (en) 2016-07-14
AU2014357450B2 true AU2014357450B2 (en) 2019-10-03

Family

ID=53274268

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014357450A Active AU2014357450B2 (en) 2013-12-03 2014-12-01 Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
AU2019229346A Abandoned AU2019229346A1 (en) 2013-12-03 2019-09-11 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019229346A Abandoned AU2019229346A1 (en) 2013-12-03 2019-09-11 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Country Status (9)

Country Link
US (2) US9926381B2 (enExample)
EP (1) EP3077010B1 (enExample)
JP (1) JP6535668B2 (enExample)
CN (1) CN106456809B (enExample)
AU (2) AU2014357450B2 (enExample)
CA (1) CA2931779C (enExample)
IL (1) IL245880B (enExample)
SG (1) SG10201709164UA (enExample)
WO (1) WO2015084736A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127827A1 (de) * 2018-12-20 2020-06-25 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220416A1 (en) * 2006-05-03 2009-09-03 Sydney Welt Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004005A1 (en) 1989-09-15 1991-04-04 Akzo N.V. Compartmentalized container for a plurality of small articles
ATE148348T1 (de) * 1989-09-15 1997-02-15 Tanox Biosystems Inc Behandlung von einer autoimmun-krankheit
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2008027986A2 (en) * 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CN101965363A (zh) * 2006-11-02 2011-02-02 丹尼尔·J·卡鹏 具有活动部分的杂合免疫球蛋白
EP1972640A1 (en) * 2007-03-23 2008-09-24 Biomay AG Apoptosis inducing antibodies
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220416A1 (en) * 2006-05-03 2009-09-03 Sydney Welt Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders

Also Published As

Publication number Publication date
CA2931779C (en) 2023-04-25
US9926381B2 (en) 2018-03-27
JP6535668B2 (ja) 2019-06-26
WO2015084736A4 (en) 2016-02-25
IL245880B (en) 2020-09-30
AU2014357450A1 (en) 2016-07-14
WO2015084736A2 (en) 2015-06-11
JP2016540504A (ja) 2016-12-28
SG10201709164UA (en) 2017-12-28
CN106456809A (zh) 2017-02-22
IL245880A0 (en) 2016-07-31
CN106456809B (zh) 2020-02-07
CA2931779A1 (en) 2015-06-11
EP3077010A2 (en) 2016-10-12
WO2015084736A3 (en) 2016-01-21
AU2019229346A1 (en) 2019-10-03
US10227419B2 (en) 2019-03-12
US20180186895A1 (en) 2018-07-05
EP3077010B1 (en) 2020-04-01
US20160304625A1 (en) 2016-10-20
EP3077010A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CN104013957B (zh) 用新的抗il13单克隆抗体治疗癌症
US9518124B2 (en) Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
US20100136030A1 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US10227419B2 (en) Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
DK2324060T3 (en) ANTI-EXTENDED TYPE I glycosphingolipid ANTIBODY, DERIVATIVES AND USE
AU2013201832B2 (en) Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
HK1201457B (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
HK1157363B (en) Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)